May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
AdPEDF Therapy for Subfoveal Choroidal Neovascularization (CNV): Preliminary Phase I Results
Author Affiliations & Notes
  • P. Campochiaro
    Wilmer Eye Institute, Baltimore, MD
  • M. Klein
    Casey Eye Institute, Portland, OR
  • E. Holz
    Cullen Eye Institute, Houston, TX
  • A. Gupta
    Jules Stein Eye Institute, Los Angeles, CA
  • D. Saperstein
    University of Washington, Seattle, WA
  • S. Bressler
    Wilmer Eye Institute, Baltimore, MD
  • L.L. Wei
    GenVec, Inc., Gaithersburg, MD
  • A. Ray
    GenVec, Inc., Gaithersburg, MD
  • R.N. Frank
    Kresge Eye Institute, Detroit, MD
  • T. Stout
    Casey Eye Institute, Portland, OR
  • Footnotes
    Commercial Relationships  P. Campochiaro, GenVec, Inc. F; M. Klein, None; E. Holz, None; A. Gupta, None; D. Saperstein, None; S. Bressler, GenVec, Inc. C; L.L. Wei, GenVec, Inc. E; A. Ray, GenVec, Inc. E; R.N. Frank, None; T. Stout, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2361. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Campochiaro, M. Klein, E. Holz, A. Gupta, D. Saperstein, S. Bressler, L.L. Wei, A. Ray, R.N. Frank, T. Stout; AdPEDF Therapy for Subfoveal Choroidal Neovascularization (CNV): Preliminary Phase I Results . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2361.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate the safety and feasibility of intravitreous AdPEDF in patients with subfoveal CNV due to age–related macular degeneration (AMD). Methods: Open label, dose–escalation design with 8 dose levels (106–109.5 pu in ½ log increments) in patients with subfoveal CNV ≤ 12 MPS disc areas and best corrected visual acuity of 20/200 or worse in study eye. After a single intravitreous injection of AdPEDF, 1 year follow–up consisted of periodic ocular exams, fluorescein angiograms, and laboratory evaluations including adenovirus neutralizing antibody titers and throat and urine cultures for adenovirus. Optical Coherence Tomography was performed as a substudy at 2 study sites. Results: Six of 8 dose cohorts have been fully enrolled (n=18), and accrual is ongoing. Intravitreous AdPEDF has been well–tolerated and there have been no dose limiting toxicities or related severe adverse events. Three patients (two at 107.5 and one at 108.5 pu) had mild transient inflammation and Grade 1 elevation in IOP thought to be probably or possibly related to the study drug. Neutralizing antibody titers did not increase at 3 months in 11 out of 12 patients and all adenoviral cultures were negative. Conclusions: Intravitreous injection of up to 108.5 pu of AdPEDF is well–tolerated and has not been associated with any serious short–term toxicity.

Keywords: age–related macular degeneration • gene transfer/gene therapy • adenovirus 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.